Epstein-Barr Virus Infection
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
RNA Therapeutic
2100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
ModernaCAMBRIDGE, MA
2 programs1
1
mRNA-1189Phase 1/2RNA Therapeutic1 trial
mRNA-1195.1Phase 1RNA Therapeutic1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ModernamRNA-1189
ModernamRNA-1195.1
Clinical Trials (2)
Total enrollment: 1,349 patients across 2 trials
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
Start: Dec 2021Est. completion: Oct 2026867 patients
Phase 1/2Active Not Recruiting
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
Start: Apr 2023Est. completion: Oct 2026482 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space